Clinical and laboratory characteristics of tAML patients according to the TP53 germ line status
| . | TP53 germ line status . | P value . | |
|---|---|---|---|
| Wild-type . | Mutated . | ||
| Number of patients (n) | 101 | 6 | .221 |
| Females/males, n (%) | 54 (53)/47 (47) | 5 (83)/1 (17) | |
| Age at diagnosis (y) | 65 (19-85) | 53 (8-80) | .263 |
| LDH (U/L) | 268 (121-2489) | 413 (127-543) | .948 |
| WBC at diagnosis (109/L) | 4.14 (0.81-305.7) | 2.62 (1.47-16.15) | .313 |
| Antecedent cytotoxic therapy, n (%) | |||
| Ionizing radiation | 38/101 (38) | 5/6 (83) | .038 |
| Alkylating agents | 48/101 (48) | 2/5 (40)* | .999 |
| Antimetabolites | 47/101 (47) | 1/5 (20)* | .374 |
| Topoisomerase inhibitors | 18/101 (18) | 2/5 (40)* | .237 |
| . | TP53 germ line status . | P value . | |
|---|---|---|---|
| Wild-type . | Mutated . | ||
| Number of patients (n) | 101 | 6 | .221 |
| Females/males, n (%) | 54 (53)/47 (47) | 5 (83)/1 (17) | |
| Age at diagnosis (y) | 65 (19-85) | 53 (8-80) | .263 |
| LDH (U/L) | 268 (121-2489) | 413 (127-543) | .948 |
| WBC at diagnosis (109/L) | 4.14 (0.81-305.7) | 2.62 (1.47-16.15) | .313 |
| Antecedent cytotoxic therapy, n (%) | |||
| Ionizing radiation | 38/101 (38) | 5/6 (83) | .038 |
| Alkylating agents | 48/101 (48) | 2/5 (40)* | .999 |
| Antimetabolites | 47/101 (47) | 1/5 (20)* | .374 |
| Topoisomerase inhibitors | 18/101 (18) | 2/5 (40)* | .237 |
One patient, whose chemotherapeutic agents administered for the primary malignancies were unknown, was excluded from statistical calculations.
LDH, lactate dehydrogenase; WBC, white blood cell count.
Cytotoxic therapies with leukemogenic potential were classified according to Sill et al.25